Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

HOW INSTAGRAM SCALED TO 14 MILLION USERS WITH ONLY 3 ENGINEERS

Instagram went from 0 to 14 million users in just over a year and it did it with only three engineers. Its tech stack was surprisingly simple, using AWS extensively and a monolithic Django backend. It also used various caching tools like Redis and Memcached for better performance as it scaled. This article provides a visual explanation of Instagram’s tech stack by walking through the architecture using the life of a request.

SPYWARE FOUND ON THE PHONE OF PROMINENT RUSSIAN JOURNALIST

Meduza co-founder Galina Timchenko's phone was infected with Pegasus spyware, making her the first Russian journalist to be targeted. The software is marketed exclusively to state clients for use against criminals, but has been used to target journalists, activists, and politicians around the world. Meduza worked with experts to investigate the attack and learn which states may have spent millions of dollars to hijack Timchenko's phone.

ENTITIES

Genesis, a crypto firm and subsidiary of DCG, is discontinuing its spot and derivatives trading operations. The change will take effect immediately, with existing open derivatives positions being honored until expiry. A spokesperson confirmed that the company no longer offers trading services through any of its business entities. This decision follows a similar move last week, when Genesis Global Trading ended its crypto spot trading operations, citing strategic reasons.

HUMAN TRIALS OF ARTIFICIAL WOMBS COULD START SOON

Researchers at the Children's Hospital of Philadelphia are seeking approval for the first human clinical trials of its artificial wombs. The technology is not designed to support development from conception to birth. However, it may help improve outcomes for extremely premature babies. The FDA will convene a meeting of independent advisers on 19-20 September to discuss regulatory and ethical considerations around what human trials for the technology might look like.

TLDR IndexPage 1